Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Compare the Safety and Efficacy of 3 Dose Levels of AV-1 in Healthy Adults Challenged With a Controlled Human Infection Strain of DENV-3
Conditions
Interventions
AV-1 100 mg
AV-1 300 mg
+2 more
Locations
3
United States
Center for Immunization Research (CIR) JHBSPH
Baltimore, Maryland, United States
Center for Immunization Research Inpatient Unit
Baltimore, Maryland, United States
UVM Larner College of Medicine Department of MMG
Burlington, Vermont, United States
Start Date
January 7, 2025
Primary Completion Date
March 14, 2026
Completion Date
March 14, 2026
Last Updated
October 20, 2025
Lead Sponsor
AbViro LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions